Search

Search bills, members, committees and pages...

S. 297

U.S. SenateIn Senate Committee

Summary

S. 297, the PSA Screening for HIM Act, was introduced in the Senate on Jan 29, 2025 by Sen. John Boozman (R) with 6 co-sponsors. It was referred to Health, Education, Labor, And Pensions, and last saw action on Mar 19, 2026: Committee on Health, Education, Labor, and Pensions. Hearings held.


Record

Text

S. 297 has 6 co-sponsors.

sb297/introduced-in-senate.txt
119 S297 IS: Prostate-Specific Antigen Screening for High-risk Insured Men Act
U.S. Senate
2025-01-29
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
II 119th CONGRESS 1st Session S. 297 IN THE SENATE OF THE UNITED STATES January 29, 2025 Mr. Boozman (for himself and Mr. Booker ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL
To amend title XXVII of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without the imposition of cost-sharing requirements, and for other purposes.
1.
Short title
This Act may be cited as the Prostate-Specific Antigen Screening for High-risk Insured Men Act or the PSA Screening for HIM Act .
2.
Findings
Congress finds the following:
(1)
Prostate cancer is the second leading cause of cancer death in men in the United States with 1 in 44 men dying from prostate cancer and more than 35,700 men estimated to die from prostate cancer in 2025.
(2)
Prostate cancer is the second most commonly diagnosed cancer in the Nation with 1 in 8 men being diagnosed in their lifetimes, 3,300,000 men in the United States living with a diagnosis, and over 310,000 men estimated to be diagnosed in 2025.
(3)
The survival rate for prostate cancer diagnosed in early stage is near 100 percent but prostate cancer diagnosed in late stage has only a 37-percent survival rate.
(4)
There are few, if any, symptoms of prostate cancer before it reaches late stage.
(5)
African-American men have a disproportionately higher rate of prostate cancer and are 70 percent more likely to be diagnosed with prostate cancer than White men, with 1 in 6 African-American men developing prostate cancer in their lifetimes.
(6)
African-American men are 2.1 times more likely to die from prostate cancer than White men.
(7)
Men with a father or brother with prostate cancer are more than twice as likely to be diagnosed with prostate cancer than men without a family history.
(8)
The common clinical definition for men at high-risk of prostate cancer includes African-American men and men with a family history.
(9)
Most of the major cancer and urological societies recommend beginning screening discussions earlier for African-American men and those with a family history of prostate cancer.
(10)
The United States Preventive Services Task Force has encouraged research on screening African-American men, including whether to screen African-American men at younger ages, and has identified this research as a high-priority cancer research gap.
(11)
Barriers to screening should be minimized for high-risk men in order to catch asymptomatic prostate cancer before it metastasizes and the survival rate is dramatically reduced.
(12)
The cost of treating metastatic prostate cancer in the United States health care system is hundreds of millions of dollars more annually than the cost of treating localized, early-stage cancer.
3.
Requirement for group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without imposition of cost-sharing requirements
(a)
In general
Section 2713(a) of the Public Health Service Act ( 42 U.S.C. 300gg–13(a) ) is amended—
(1)
by striking paragraph (5);
(2)
by redesignating paragraphs (1) through (4) as subparagraphs (A) through (D), respectively, and adjusting the margins accordingly;
(3)
by striking (a)
In general— A group health and inserting the following:
(a)
Coverage of preventive health services
(1)
In general
A group health
;
(4)
in paragraph (1), as so designated—
(A)
in subparagraph (B), as so redesignated, by striking ; and and inserting a semicolon;
(B)
in subparagraph (C), as so redesignated, by striking the period and inserting a semicolon;
(C)
in subparagraph (D), as so redesignated—
(i)
by striking paragraph (1) and inserting subparagraph (A) ; and
(ii)
by striking the period and inserting ; and ;
(D)
by inserting after subparagraph (D), as so redesignated, the following:
(E)
with respect to men who are age 40 and over and are at high risk of developing prostate cancer (including African-American men and men with a family history of prostate cancer (as defined in paragraph (2))), such additional evidence-based preventive care and screenings not described in subparagraph (A) for prostate cancer.
; and
(5)
by striking the flush text at the end and inserting the following:
(2)
Men with a family history of prostate cancer defined
For purposes of paragraph (1)(E), the term men with a family history of prostate cancer means men who have a first-degree relative—
(A)
who was diagnosed with prostate cancer;
(B)
who developed prostate cancer;
(C)
whose death was a result of prostate cancer;
(D)
who have been diagnosed with a cancer known to be associated with increased risk of prostate cancer; or
(E)
who has a genetic alteration known to be associated with increased risk of prostate cancer.
(3)
Clarification regarding breast cancer screening, mammography, and prevention recommendations
For the purposes of this Act, and for the purposes of any other provision of law, the current recommendations of the United States Preventive Service Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current other than those issued in or around November 2009.
(4)
Rule of construction
Nothing in this subsection shall be construed to prohibit a plan or issuer from providing coverage for services in addition to those recommended by the United States Preventive Services Task Force or to deny coverage for services that are not recommended by such Task Force.
.
(b)
Effective date
The amendments made by subsection (a) shall apply with respect to plan years beginning on or after January 1, 2025.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-01-29
  2. Passed Senate
  3. Passed House
  4. Conference
  5. To President
  6. Became Law

A bill to amend title XXVII of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without the imposition of cost-sharing requirements, and for other purposes.

Sponsors

Sen. John Boozman (R) sponsors S. 297, and 6 members have co-sponsored it, 1 of them from the day it was introduced.

Committees

S. 297 went before 1 committee: Health, Education, Labor, and Pensions.

Health, Education, Labor, and Pensions
Health, Education, Labor, and Pensions
Hearings By (full committee) · Mar 19, 2026 · 747 Bills

Actions

S. 297 has taken 3 actions since Jan 29, 2025, the latest on Mar 19, 2026.

ChamberAction
Mar 19, 2026
Senate
Committee on Health, Education, Labor, and Pensions. Hearings held.Health, Education, Labor, and Pensions Committee
Jan 29, 2025
Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Health, Education, Labor, and Pensions Committee
Jan 29, 2025
Introduced in Senate

Votes

S. 297 has not gone to a roll call.

Titles

S. 297 goes by 4 titles, 2 of them short titles.

  • PSA Screening for HIM Act — Display Title
  • PSA Screening for HIM Act — Short Title(s) as Introduced
  • Prostate-Specific Antigen Screening for High-risk Insured Men Act — Short Title(s) as Introduced
  • A bill to amend title XXVII of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without the imposition of cost-sharing requirements, and for other purposes. — Official Title as Introduced

Lobbying

7 clients hired 7 firms and 36 registered lobbyists who named S. 297 in 19 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Budget/Appropriations, Medical/Disease Research/Clinical Labs, Copyright/Patent/Trademark, Defense, Indian/Native American Affairs.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCDistrict of Columbia16
ASTELLAS PHARMA US, INC.Illinois16
AMERICAN UROLOGICAL ASSOCIATIONPremier urologic association, providing invaluable support to the urologic communityMaryland12$60K
DENDREON PHARMACEUTICALS LLCBiopharmaceutical company.California12$60K
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)District of Columbia11
NATIONAL ASSOCIATION OF NUCLEAR PHARMACIESNon-profit industry association of over four hundred nuclear pharmaciesDistrict of Columbia11
VANDERBILT UNIVERSITY MEDICAL CENTERTennessee11

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 36.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2025 first_quarter$4.8M1st Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2025 second_quarter$2.6M2nd Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2025 fourth_quarter$2.4M4th Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2026 first_quarter$2.3M1st Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2025 third_quarter$2.1M3rd Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2025 first_quarter$2M1st Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2026 second_quarter$1.2M2nd Quarter - Report
ASTELLAS PHARMA US, INC.ASTELLAS PHARMA US, INC.2025 fourth_quarter$980K4th Quarter - Report
ASTELLAS PHARMA US, INC.ASTELLAS PHARMA US, INC.2025 third_quarter$850K3rd Quarter - Report
ASTELLAS PHARMA US, INC.ASTELLAS PHARMA US, INC.2025 second_quarter$670K2nd Quarter - Report
ASTELLAS PHARMA US, INC.ASTELLAS PHARMA US, INC.2026 first_quarter$590K1st Quarter - Report
ASTELLAS PHARMA US, INC.ASTELLAS PHARMA US, INC.2025 first_quarter$560K1st Quarter - Report
ASTELLAS PHARMA US, INC.ASTELLAS PHARMA US, INC.2026 second_quarter$510K2nd Quarter - Report
VANDERBILT UNIVERSITY MEDICAL CENTERVANDERBILT UNIVERSITY MEDICAL CENTER2025 fourth_quarter$50K4th Quarter - Report
AMERICAN UROLOGICAL ASSOCIATIONVENABLE LLP2025 fourth_quarter$30K4th Quarter - Termina…
AMERICAN UROLOGICAL ASSOCIATIONVENABLE LLP2025 third_quarter$30K3rd Quarter - Report
DENDREON PHARMACEUTICALS LLCTHE MCMANUS GROUP2025 second_quarter$30K2nd Quarter - Report
DENDREON PHARMACEUTICALS LLCTHE MCMANUS GROUP2025 first_quarter$30K1st Quarter - Report
NATIONAL ASSOCIATION OF NUCLEAR PHARMACIESBOSE PUBLIC AFFAIRS GROUP2025 third_quarter3rd Quarter - Report

Classification

The Congressional Research Service files S. 297 under Health, one of its 31 policy areas, and gives it 5 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; S. 297’s is Health.

s297/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Legislative Subjects

S. 297 carries 5 of CRS’s legislative subjects, from Cancer to Medical tests and diagnostic methods.

s297/subjects.txt
CancerHealth care costs and insuranceHealth care coverage and accessHealth promotion and preventive careMedical tests and diagnostic methods

Source: congress.gov · legiscan.com